Contrast injector developer ACIST Medical Systems is launching a new contrast delivery system at this week's Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC.
ACIST CVi is a new system that combines into one platform all of the features of ACIST's CMS and Voyager products. The device can be used for both cardiac and vascular angiography, according to ACIST, a subsidiary of Italian contract developer Bracco. The unit also features a lower-profile table-mounted injector and extendable control panel that can be placed where needed and that reduces the amount of equipment in the procedure room.
Commercial shipments of ACIST CVi should begin in the first quarter of 2006 or earlier, according to the company.
By AuntMinnie.com staff writers
October 18, 2005
Related Reading
Bracco to acquire injector firm Acist, June 20, 2001
Acist gets FDA nod for Voyager, March 13, 2001
FDA clears Acist contrast injector, June 5, 2000
Copyright © 2005 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
